Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | RELA | Q04206 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | GAA | P10253 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 5/20 | 0.44 |
| ▸ | RAB9A | P51151 | 5/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12676963 | 0.87 | RELA (0.49) | EGFRRELAALDH1A1GAAKDM4E | |
| SCHEMBL13595004 | 0.87 | CYP11B1 (0.49) | EGFRALDH1A1GAAKDM4ENPC1 | |
| SCHEMBL12676802 | 0.86 | S100A4 (0.50) | EGFRRELAALDH1A1GAAKDM4E | |
| SCHEMBL12409504 | 0.84 | ALDH1A1 (0.48) | EGFRALDH1A1GAAKDM4ELMNA | |
| SCHEMBL13595001 | 0.83 | HRH4 (0.42) | EGFRRELAALDH1A1GAAKDM4E | |
| SCHEMBL8219137 | 0.82 | KDM4E (0.48) | ALDH1A1GAAKDM4EPDGFRBPDGFRA | |
| SCHEMBL7926375 | 0.79 | ALDH1A1 (0.60) | ALDH1A1GAAKDM4ELMNAHSD17B10 | |
| SCHEMBL13595019 | 0.79 | HRH4 (0.46) | EGFRALDH1A1GAAKDM4ELMNA | |
| SCHEMBL12676965 | 0.79 | HRH4 (0.46) | EGFRALDH1A1GAAKDM4ELMNA | |
| SCHEMBL12669907 | 0.78 | RAB9A (0.44) | EGFRRELAALDH1A1GAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809264-B2 | Quinoxalinyl macrocyclic hepatitis C virus serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-RE42375-E1 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7635683-B2 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7605126-B2 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-7368452-B2 | Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-05-06 | — | — | US | disclosed |
| US-20080039470-A1 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-01-10 | — | — | US | disclosed |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | ENANTA PHARMACEUTICALS, INC. | 2007-12-27 | — | — | US | disclosed |
| US-7176208-B2 | Prevent reproduction of hepatitis virus | ENANTA PHARMACEUTICALS, INC. (US) | 2007-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039470-A1 | Acylaminoheteroaryl hepatitis C virus protease inhibitors | ATG4A, CYP4A22, AADAC | EGFR 2626/4885RELA 869/4885ALDH1A1 486/4885 |
| US-20080008681-A1 | MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, TMPRSS4 | EGFR 2823/4885RELA 959/4885ALDH1A1 1236/4885 |
| US-20090005387-A1 | QUINOXALINYL MACROCYCLIC HEPATITIS C VIRUS SERINE PROTEASE INHIBITORS | PRSS1, SPINT2, CTSC | EGFR 4091/4885RELA 821/4885ALDH1A1 1344/4885 |
| US-20070299078-A1 | Quinoxalinyl Macrocyclic Hepatitis C Virus Serine Protease Inhibitors | PRSS1, SPINT2, CTSC | EGFR 4091/4885RELA 821/4885ALDH1A1 1344/4885 |
| US-20080032936-A1 | Quinoxalinyl tripeptide hepatitis C virus inhibitors | VIP, CTSC, PREP | EGFR 4226/4885RELA 802/4885ALDH1A1 1229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.